It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is making larger doses available for $499 through its self-pay program.

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly and Company (NYSE ... U.S. capital expansion commitments to more than $50 billion since 2020. SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ...

(NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with ...

Eli Lilly has acquired Organovo’s lead asset ... $9 million upfront plus another $1 million after 15 months to the San Diego biotech, according to Securities and Exchange Commission (SEC ...

With grant funding from governments at multiple levels in Canada, Entos Pharmaceuticals is looking to plant roots at a CAD $198.5 million ($137.2 million) R&D and manufacturing hub in Edmonton. | The ...

What To Know: San Diego-based biotechnology company Organovo announced that Eli Lilly will acquire its FXR program, including lead asset FXR314, aimed at treating inflammatory bowel disease.

Entos Pharmaceuticals has announced an investment of C$62m ($43.05m) from the governments of Canada and Alberta for an R&D facility.

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE ... approaches in inflammatory bowel disease (IBD) today announced that Eli Lilly and Company (NYSE:LLY) (“Lilly”) will acquire Organovo’s ...